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Summary 
 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst 
women of reproductive age. Although PCOS is diagnosed exclusively based on reproductive 
criteria (clinical/biochemical hyperandrogenism, an/oligo-ovulation, and/or polycystic ovaries 
(PCO) on ultrasound), it is also a metabolic disorder. Insulin resistance, impaired glucose 
tolerance, type 2 diabetes mellitus, obesity and dyslipidemia are more common in women with 
PCOS than in age-comparable women without PCOS. Many of the metabolic abnormalities that 
manifest in PCOS, such as insulin resistance, impaired glucose tolerance, type 2 diabetes 
mellitus, and dyslipidemia are worsened by the concurrent incidence of obesity. However, some 
of these metabolic perturbations occur even in lean women with PCOS and therefore are 
rightfully recognized as intrinsic to PCOS. The intrinsic factors that produce these metabolic 
disturbances are reviewed in this thesis paper. Regarding obesity as both an amplifying factor for 
other disturbances and as a PCOS-induced disturbance is legitimate, as obesity exacerbates the 
other PCOS-induced disturbances yet, it is itself an intrinsic PCOS-induced disturbance since it 
arises more frequently in PCOS women than in control cohorts. The consequences of obesity and 
the other metabolic aberrations are also discussed. Most importantly, these metabolic 
perturbations lead to chronic low grade inflammation and to cardiovascular impairments that 
heighten the risk of having cardiovascular disease. Following a review of cardiovascular 
impairments and cardiovascular events that have been reported in studies on women with PCOS, 
this paper then proceeds to discuss therapies currently implemented to minimize these 
cardiovascular risks. Therapies such as oral contraceptives and anti-androgenic medications used 
to manage the reproductive manifestations of PCOS may themselves be a cause of metabolic 
perturbations. Therefore, factors influencing the cardiometabolic side effects arising during the 
treatment of the non-metabolic manifestations of PCOS (hirsutism/anovulation) will also be 
discussed in an effort to minimize the overall cardiometabolic risk. 
Key words: PCOS Insulin resistance Metabolic Syndrome  Cardiovascular Disease 
   Cardiovascular Risk Factors 
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Introduction 
 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst 
women of reproductive age. It is a heterogeneous disorder of uncertain etiology, but there is 
strong evidence that complex interactions between genetic, environmental and behavioral factors 
contribute to causing this syndrome (Bargiota and Diamanti 2012). PCOS affects as many as 
10% of reproductive-age women when using the NIH criteria for diagnosis, and up to 18% of 
reproductive-age women are diagnosed with PCOS per the Rotterdam criteria (March et al. 
2010). Nevertheless, at least 70% of PCOS cases remain undiagnosed in primary care 
(Tomlinson et al. 2013). 
Although the diagnosis of PCOS is based exclusively on reproductive criteria 
(hyperandrogenism, oligo/an-ovulation, and/or PCO on ultrasound) (Hoffman and Ehrmann 
2008), and management tends to focus primarily on treatment of infertility and hirsutism (Teede 
et al. 2010), PCOS is also a metabolic disorder. Women with PCOS have an increased risk of 
presenting with insulin resistance (IR) (Diamanti-Kandarakis and Dunaif 2012), impaired 
glucose tolerance (IGT) (Moran et al. 2010), type 2 diabetes mellitus (DM2) (Moran et al. 2010), 
obesity (Diamanti-Kandarakis and Dunaif 2012), and dyslipidemia (Randeva et al. 2012). In 
addition to presenting with these traditional risk factors for CVD, women with PCOS also show 
evidence of an increase of nontraditional, novel CVD risk factors, such as subclinical 
atherosclerosis (Orio et al. 2004a) and an elevation in inflammatory markers (Escobar-Morreale 
et al. 2011). As PCOS seems to be dominated by metabolic consequences, both as a consequence 
of the condition and as a vector for further complications, including DM2, CVD, and the 
exacerbation of the reproductive features of the syndrome (hirsutism and an/oligoovulation) 
(Teede et al. 2010), it is evident that research on the metabolic and cardiometabolic features of 
PCOS is needed. The present review is a contribution to this overall effort. The sections that 
follow discuss the cardiometabolic aspects of PCOS, their potential causes, their associated risks, 
and possible screening measures and therapies. 
The presentation of many of the topics addressed in the present work follows the same 
logical progression as that of the paper by Randeva et al. (Randeva et al. 2012).  Hence many of 
the top level section headings will resemble those of that paper.  However, the technical content 
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and inner organization within each section are original and substantially different from those of 
the paper by Randeva et al (Randeva et al. 2012). In particular, many new subjects are addressed 
and many others are examined in significantly more depth than those of that paper as well as 
those of reviews by other authors. 
Methods 
 
An extensive literature search was conducted to review publications from the late 1980’s 
to the present. Online sources of medical databases included the U.S. National Library of 
Medicine (NLM), the National center for Biotechnology Information (NCBI) at the NLM, the 
Helios Group Central Medical Library, PubMed and MedScape. The search was conducted with 
a combination of terms that included “PCOS,” ”cardiometabolic,” “cardiovascular disease,” 
“metabolic syndrome,” “insulin resistance,” “obesity,” and many others that were assumed to be 
relevant. Articles were also selected among references in the published papers found in the 
automated searches. Studies and review articles covering the focused areas were then selected. 
Diagnosis of PCOS 
Commonly used Criteria 
 
Three different sets of criteria have been used for the diagnosis of PCOS for the past two 
decades: the National Institutes of Child Health and Human Development (NICHD) or what is 
known as the NIH criteria (developed in 1990), the Rotterdam criteria (adopted at a PCOS 
consensus meeting held in 2003), and the Androgen Excess (AE) and PCOS Society (AE-PCOS) 
criteria (proposed in 2006) (Teede et al. 2010). These criteria are summarized in Table 1. 
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Table 1: PCOS Diagnostic Criteria, adapted from Teede et al. 2010. 
NIH 1990  Rotterdam 2003 AE-PCOS Society 2006 
Both of the following: 
 Chronic anovulation, 
documented by oligo-or 
amenorrhea and  
 Clinical and/or 
biochemical signs of 
hyperandrogenism 
(with exclusion of other 
etiologies, e.g., congenital 
adrenal hyperplasia) 
 
with or without PCO on 
ultrasound 
At least two of the following: 
Chronic anovulation, 
documented by oligo-or 
amenorrhea 
 Clinical and/or 
biochemical signs of 
hyperandrogenism 
 Polycystic ovaries (by 
ultrasound) 
 
 Clinical and/or 
biochemical 
signs of hyperandrogenism, 
and  
 
at least one of the following: 
 Ovarian dysfunction 
(Oligo-anovulation 
and/or polycystic ovarian 
morphology) 
 
Metabolic profiles of the diagnostic phenotypes 
 
The different diagnostic criteria create several phenotypes of PCOS. Even before the 
Rotterdam criteria were adopted, it was evident that different subgroups of PCOS existed and it 
was even suggested that these subgroups differed metabolically (Diamanti and Dunaif 2012). 
One extensive review by Moran and Teede sought to compare the metabolic profiles among 
these different reproductive phenotypes (Moran and Teede 2009). For simplification, the 
phenotypes were divided into four diagnostic groups: Phenotype A (NIH –PCOS of 
biochemical/clinical hyperandrogenism and oligo/anovulation with PCO); Phenotype B (NIH – 
PCOS of biochemical/clinical hyperandrogenism and oligo/anovulation without PCO ); 
Phenotype C (non-NIH PCOS with biochemical/clinical hyperandrogenism and PCO but with 
normal ovulation; Phenotype D (non-NIH PCOS with oligo/an-ovulation and PCO but without 
any biochemical/clinical hyperandrogenism) (Moran and Teede 2009). The diagnostic criteria of 
each of these four phenotypes are summarized in table 2. 
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Table 2: Diagnostic phenotypes of PCOS, adapted from Moran and Teede (2009). 
  
Phenotype A NIH-PCOS: hyperandrogenism and 
oligo/anovulation with PCO 
Phenotype B NIH PCOS: hyperandrogenism and 
oligo/anovulation without PCO: 
Phenotype C Non-NIH PCOS: hyperandrogenism with PCO 
but with normal ovulation 
Phenotype D Non-NIH PCOS: No hyperandrogenism but with 
oligo/anovulation and with PCO 
 
Most studies comparing the two subtypes of NIH PCOS, phenotypes A and B, report that 
women diagnosed under phenotype A present with few, if any, differences in metabolic profiles 
compared with women having phenotype B PCOS (Moran and Teede 2009). Similarly, most 
studies limiting comparison to only non-NIH subtypes, phenotypes C and D, also agree that 
women with phenotype C PCOS do not present with different metabolic risks compared to 
women with phenotype D PCOS (Moran and Teede 2009). However, most studies conclude that 
women with NIH PCOS (phenotypes A and B) present with more adverse metabolic profiles 
(including higher IR, increased prevalence of metabolic syndrome and more adverse lipid 
profiles) than those with non-NIH PCOS (phenotypes C and D) (Moran and Teede 2009).  
Studies comparing women categorized under the NIH and non-NIH PCOS groups, but only after 
matching the subjects for BMI and WHR, found that the metabolic profiles (degree of IR, 
metabolic syndrome prevalence and lipid profiles) are similar in the NIH and non-NIH PCOS 
women (Moran and Teede 2009). These results suggest that although NIH phenotypes present 
with more adverse metabolic profiles, the worse metabolic profile is not an inherent feature of 
NIH PCOS but is related to excess adiposity, particularly abdominal adiposity, which is more 
common in NIH PCOS groups (Moran and Teede 2009). 
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Cardiometabolic Aspects of PCOS 
 
Insulin Resistance and Hyperinsulinemia 
 
Insulin resistance occurs in 30% of lean women with PCOS (Randeva et al. 2012) and 
95% of obese women with PCOS (Wild et al. 2010). Overall, 60-80% of women with PCOS are 
insulin resistant (Wild et al. 2010). As these statistics illustrate, insulin resistance in PCOS 
occurs independently of obesity, although excess adiposity, possibly by enhancing the 
production and secretion of certain adipokines and inflammatory factors (discussed in further 
sections), exacerbates insulin resistance. 
The Impact of Insulin Resistance in PCOS 
 
Insulin resistance (IR) and compensatory hyperinsulinemia produce many complications 
in PCOS. 
Insulin binds to its cognate receptor on ovarian theca cells and enhances LH-stimulated 
androgen production (Cara and Rosenfield 1988). IR in PCOS interferes with glucose 
metabolism, without affecting insulin’s mitogenic actions, nor insulin-mediated androgen 
synthesis (Diamanti-Kandarakis and Dunaif 2012). The compensatory hyperinsulinemia that 
ensues increases ovarian androgen production, contributing in part to the hyperandrogenemia 
observed in PCOS (Teede et al. 2010). Insulin also inhibits the hepatic production of sex 
hormone binding globulin (SHBG) (Nestler et al. 1991). Thus, hyperinsulinemia decreases 
SHBG production, which results in an increase of free, biologically active testosterone levels 
(Nestler et al. 1991). Interestingly, in a study by Kauffman et al., levels of free testosterone 
directly correlated with the measures of IR in each woman with NIH-diagnosed PCOS 
(Kauffman et al. 2008). Although IR can exacerbate hyperandrogenism in PCOS, and there has 
been debate as to whether hyperandrogenism or IR occurs first, evidence points out that 
hyperandrogenemism probably occurs before IR. Studies have demonstrated that women with 
high insulin levels from insulinomas or from exogenous sources do not develop 
hyperandrogenism, whereas in other studies, testosterone administration to healthy transsexual 
women or to female rats was followed by IR (Tiras et al. 1999). 
6 
 
Insulin also enhances cholesterol transport into arteriolar smooth muscle cells, and 
increases cholesterol synthesis in these cells, promoting atherosclerosis (Talbott et al. 2000). 
Hyperinsulinemia in PCOS, in turn, has been associated with increased intima-media wall 
thickness (IMT), a marker of subclinical atherosclerosis (Carmina et al 2006b, Talbott et al. 
2000). In several studies of women with and without PCOS, IMT showed positive correlations 
with insulin levels (Carmina et al. 2006b, Folsom et al. 1994, Lasko et al. 1991, Talbott et al. 
2000). 
Insulin is also a major regulator of many enzymes involved in lipoprotein metabolism 
(Miccoli et al. 2007, Orio et al. 2004b). Resistance to insulin may contribute, in part, to the 
dyslipidemia observed in PCOS (Kauffman et al. 2008, Orio et al. 2004b). A detailed description 
of the steps involved in lipoprotein metabolism is beyond the scope of this review. However, it 
has been proven that IR increases the hepatic secretion of VLDL and decreases the elimination 
of VLDL and of chylomicrons (Miccoli et al. 2008). The peristence of VLDL and of 
chylomicrons in the circulaton provides a major source for triglyceride (TG) production (Miccoli 
et al. 2008). IR also leads to the more rapid clearance of apolipoprotein-a, a constituent of HDL-
C, thus reducing the production and levels of HDL-C (Miccoli et al. 2008). In several 
population-based studies each involving over 800 enrolled subjects, measures of IR correlated 
positively with levels of TG and VLDL-C, and negatively with levels of HDL-C (Miccoli et al. 
2008). In other studies, Slowinska-Srzednicka and colleagues sought to elucidate the role of 
insulin resistance in the development of lipid abnormalities in women susceptible to PCOS 
(Slowinska-Srzednicka et al. 1991). In a group of women with polycystic ovaries, after 
adjustment for age, BMI and sex hormones, regression analysis showed a strong positive 
association between fasting insulin levels and TG and VLDL-C levels, and a negative association 
between fasting insulin levels and levels of the HDL constituent apoliprotien-a (Slowinska-
Srzednicka et al. 1991). 
The high prevalence of insulin resistance in PCOS renders PCOS women 10 times more 
likely than controls to develop gestational diabetes, and up to 5 times more likely to develop 
insulin-related complications such as spontaneous abortion (Randeval et al. 2012). 
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The Pathogenesis of Insulin Resistance in PCOS 
 
The IR of PCOS is in part independent of obesity; it is primarily a result of intrinsic 
factors. A post-binding decrease in the phosphorylation of the tyrosine residues and an increase 
in the phosphorylation of the serine residues of the intracellular domain of the insulin receptor 
cause resistance to insulin’s metabolic actions (Diamanti-Kandarakis and Dunaif 2012). An 
elevation in serine phosphorylation not only decreases the responsiveness of the insulin receptor 
to its substrate, but enhances the activity of P450C17, the key enzyme of adrenal and ovarian 
steroid synthesis (Zhang et al. 1995).  The same defect in serine phosphorylation is therefore 
thought to cause both IR and hyperandrogenism in a subgroup of PCOS patients (Diamanti-
Kandarakis and Dunaif 2012). Other possible causes of insulin resistance in PCOS include 
increased serine phosphorylation of the adaptor protein IRS-1 (Diamanti-Kandarakis and Dunaif 
2012). Serine phosphorylation of the latter disrupts intracellular signaling necessary for the 
translocation of GLUT4 into the plasma membrane (Diamanti-Kandarakis and Dunaif 2012). 
Reduced expression of GLUT4 has been demonstrated in the plasma membranes of adipocytes 
of both lean and obese PCOS patients (Rosenbaum et al. 1993). Increased activation of ERK1/2 
pathways in muscle cells of PCOS women may also be responsible for resistance to insulin’s 
metabolic actions (Corbould et al. 2006, Diamanti-Kandarakis and Dunaif 2012). Although 
ERK1/2 pathways are usually involved in insulin’s mitogenic actions (Corbould et al. 2006, 
Diamanti-Kandarakis and Dunaif 2012), enhanced basal activation of ERK1/2 can also inhibit 
the IRS-1 pathways necessary for GLUT4 translocation to the plasma membrane (Corbould et al. 
2006). Increased lipolysis in visceral fat cells may contribute to the hepatic insulin resistance 
observed in obese PCOS women (Ek et al. 2002). Visceral fat cells of PCOS women demonstrate 
an enhanced lipolytic response to catecholamines (Ek et al. 2002). Enhanced lipolysis of visceral 
fat raises fatty acid and glycerol delivery to the portal vein and liver, perturbing liver function, 
eventually leading to hepatic IR, as well as to hepatic inflammation and to interference with the 
production of SHBG (Ek et al. 2002). 
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Impaired Glucose Tolerance and Type 2 Diabetes 
 
The American Diabetes Association has designated PCOS as a non-modifiable risk factor 
for type 2 diabetes (American Diabetes Association 2004). The prevalence of IGT and DM2 in 
women with PCOS, assessed in three large ethnically diverse U.S. cross-sectional studies, was 
23-35% for IGT and 4-10% for DM2, that is twice the prevalence in age- and weight- matched 
healthy women without PCOS (Diamanti-Kandarakis and Dunaif 2012). The prevalence of IGT 
and DM2 among PCOS women from other countries (Italy, Netherlands) was also found to be 
significantly higher than the prevalence in control women from the same region, although the 
overall proportion of European PCOS women having IGT or DM2 is nevertheless lower than 
that of U.S. PCOS women affected by these conditions (Diamanti-Kandarakis and Dunaif 2012). 
Authors suggest that different diagnostic criteria, diet, race and ethnicity may account for the 
higher prevalence of IGT and DM2 in U.S. PCOS women (Diamanti-Kandarakis and Dunaif 
2012, Kaufmann et al. 2008). When the PCOS women from European and U.S. studies were 
stratified according to BMI and comparisons were limited to women in comparable BMI 
categories, the differences in the prevalence of IGT and DM2 between U.S. and European PCOS 
women still persisted but decreased, highlighting the contribution of lifestyle to the disparities in 
IGT and DM2 observed between U.S. and European women (Diamanti-Kandarakis and Dunaif 
2012). Additionally, a study of two PCOS populations in the U.S., one urban ethnically diverse 
and one rural ethnically homogeneous, showed similar proportions of women with IGT and DM2 
in each of the two populations, therefore demonstrating that PCOS may be a more important risk 
factor for IGT and DM2 than factors such as race and ethnicity (Legro et al. 1999). These 
general tendencies towards a deterioration of glucose metabolism have been confirmed by a 
meta-analysis indicating a higher prevalence of IGT (odds ratio 2.54) and DM2 (odds ration 4) in 
PCOS women than in BMI matched controls (Moran et al. 2010). 
Studies have also reported higher conversion rates from normal glucose tolerance (NGT) 
to IGT and from IGT to DM2 in PCOS women (Celik et al. 2014, Legro et al. 2005). IGT is an 
independent predictor of developing DM2 (Barr et al. 2006), CVD (Barr et al. 2006, Tominaga et 
al. 1999) and of suffering mortality from CVD (Barr et al. 2006, Tominaga et al. 1999). Early 
identification and treatment of IGT with lifestyle intervention and/or metformin have been 
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shown to improve outcomes (Knowler et al. 2002). These observations have led experts at the 
most recent ESHRE/ASRM-sponsored PCOS consensus workshop to suggest the 
implementation of an annual screening of all PCOS women for IGT with the OGTT (Fauser et 
al. 2012, Tomlinson et al. 2013), the most sensitive test for assessing IGT in PCOS (Diamanti-
Kandarakis and Dunaif 2012). 
Chronic hyperinsulinemia per se exacerbates IR, leading to a higher demand for insulin 
production and eventually to β-cell burnout, thereby accelerating the progression to IGT and 
DM2 (Teede et al. 2010). Although women with PCOS have higher basal insulin secretion 
conditioned by chronic IR, they demonstrate β-cell secretory defects, manifested by reduced 
insulin secretory response to meals (O’Meara 1993) and eventually an overall secretion of 
insulin that is inadequate for the degree of IR (Dunaif and Finegood 1996). IR, β-cell secretory 
defects and eventual β-cell burnout contribute to the development of IGT and DM2 in PCOS 
(O’Meara et al. 1993). 
Obesity in PCOS 
 
The prevalence of obesity among women with PCOS in the U.S. is 70 to 80%, almost 
twice as much as in the general U.S. female population (Carmina et al. 2003, Diamanti-
Kandarakis and Dunaif 2012). Most studies report the prevalence of obesity in affected women 
outside the U.S. to be between 38 to 50% (Carmina et al. 2003, Diamanti-Kandarakis 2012). 
Differences in diagnostic criteria, environmental factors, ethnicity, and lifestyle contribute to 
these variations (Carmina et al. 2006a, Diamanti-Kandarakis and Dunaif 2012, Kauffman et al. 
2008). Although less obesity is reported outside the U.S., the prevalence of obesity among PCOS 
women outside the U.S. is still higher than that of women in the general population outside the 
U.S. (Carmina et al. 2003).  As an example, 38% of Italian PCOS women are reported to be 
obese (Carmina et al. 2003), but the reported prevalence of obesity in the general Italian female 
population is only 8% (Gallus et al. 2013), highlighting a possible contribution of PCOS per se, 
in addition to lifestyle and other factors cited above, to the pathogenesis of obesity. 
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Consequences of Obesity in PCOS 
 
Obesity plays a role in the expression of metabolic features and other clinical 
manifestations of PCOS (Diamanti-Kandarakis and Dunaif 2012, Randeva et al. 2012). IR 
appears in normal weight PCOS women, but the frequency and magnitude increases with obesity 
(Dunaif et al. 1989, Moran et al. 2012).The magnitude of IR, quantified in one study by the 
insulin to glucose ratio, demonstrated a strong, positive and linear correlation with body mass 
index (BMI) of the PCOS subjects (Moran et al. 2012). Hepatic insulin resistance, characterized 
by reduced sensitivity to insulin’s suppression of endogenous glucose production, only occurs in 
obese PCOS women (Sam et al. 2007). Obese PCOS women also have a 10-fold increase in their 
risk of suffering from DM2 and a 7-fold increase of IGT compared with normal weight (BMI 
<25 kg/m
2
) PCOS women. (Norman et al. 2001). An accelerated rate of conversion from IGT to 
DM2 is strongly dependent upon BMI (Ehrmann et al. 1999). 
Excess BMI also exacerbates the reproductive abnormalities of PCOS. One study found 
an inverse correlation between FSH levels and BMI in obese PCOS patients, as well as an 
increased prevalence of menstrual disorders (anovulation, oligo-ovulation) among obese PCOS 
women compared to non-obese ones (Kiddy et al. 2008). Obese PCOS women have responded 
less frequently to ovulation induction treatment than their non-obese counterparts (White et al. 
1996). Other studies comparing obese and non-obese PCOS women reported lower rates of 
implantation after IVF in the obese PCOS sub-group (Fedorcsák et al. 2001 and McCormick et 
al. 2008). Weight reduction of 5-10% by lifestyle modification has been shown to restore 
ovulation in anovulatory PCOS women (Huber-Buchholz et al. 1999). 
Obesity in PCOS also increases the patient’s risk of developing cardiovascular disease. 
Among PCOS women, the prevalence of the metabolic syndrome, as in the general population, 
increases with increasing BMI and is highest in obese women with PCOS (Carmina et al. 2006a). 
Studies report the prevalence of the metabolic syndrome in PCOS women in the U.S. to be 43-
47%, twice more than in the age- and BMI- matched control population, suggesting that PCOS 
per se, possibly by promoting abdominal fat accumulation, increases the risk of acquiring the 
metabolic syndrome (Carmina et al. 2006a). The effect of obesity, of causing chronic low-grade 
inflammation (Attie and Scherer 2009) with an elevation of inflammatory markers (such as CRP, 
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TNF-α and IL-6) that increase the risk of cardiovascular disease (Lind 2003), is even more 
pronounced in PCOS. In PCOS and non-PCOS women, levels of TNF-α (Gonzalez et al. 1999, 
Samy et al. 2009), IL-6 (Samy et al. 2009) and CRP (Samy et al. 2009) correlate directly with 
BMI, but overweight and obese PCOS women in some studies have presented with significantly 
higher levels of these inflammatory markers than their BMI-matched non-PCOS counterparts 
(Escobar-Morreale et al. 2011, Samy et al. 2009). 
The pathogenesis of obesity in PCOS 
 
The pathogenesis of obesity in PCOS is likely multifactorial (Faulds et al. 2003).  
One study reported that in a group of lean PCOS women, serum glycerol levels, which 
reflect lipolytic activity, were lower than glycerol levels in BMI-matched control women (Fauld 
et al. 2003). The same authors also showed that the subcutaneous adipocytes of the lean PCOS 
women were larger in size and exhibited a lower response to catecholamine-stimulated lipolysis 
than the adipocytes of the BMI-comparable control women, suggesting that decreased lipolysis 
of subcutaneous adipocytes is an early alteration in PCOS, leading to enlarged subcutaneous fat 
cells, and later to the development of obesity (Faulds et al. 2003). 
Another contributor to the high prevalence of obesity in PCOS might be mutations in the 
peroxisome proliferator-activated receptor-ɤ gene (Orio et al. 2003). A higher frequency of CT 
substitution in exon 6 of the peroxisome proliferator-activated receptor-ɤ gene has been reported 
in PCOS women than in BMI-matched controls (Orio et al. 2003). This substitution enhances the 
differentiation of fibroblasts and undifferentiated cells into mature adipocytes, possibly leading 
to obesity (Orio et al. 2003).  
Several studies also report that women with PCOS (McCluskey et al. 1991, Hirschberg et 
al. 2004) or with PCO morphology on ultrasound (Jahanfar et al. 1995) have a higher prevalence 
of bulimic behavior, in part because of increased androgens (Naessém et al. 2006), which 
increase appetite and inhibit impulse control (Naessém et al. 2006). After treatment with 
flutamide (Sunbald et al. 2005) or with anti-androgenic oral contraceptives (Naessén et al. 2007), 
a reduction of binge eating and meal-related hunger, respectively, has been reported in bulimic 
women, supporting the idea that androgens may play a role in appetite dysregulation and in the 
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development of obesity in PCOS (Naessém et al. 2006). Women with PCOS, in comparison to 
BMI-matched controls, also have reduced secretion of the gastro-intestinal satiety peptide 
cholecystokinin (Hirschberg et al. 2004) and have dysregulated secretion of the appetite-
regulating gut hormone ghrelin (Barber et al. 2008a, Moran et al. 2004) that is independent of 
diet. These alterations may cause the reduction in satiety that has been reported by PCOS 
patients in comparison to BMI-matched control women (Hirschberg et al. 2004, Moran et al. 
2004). 
Additionally, it is widely believed that ghrelin’s actions are mediated centrally by 
neuropeptide Y (NPY) and by the system of NPY fibers (Barber et al. 2008a). NPY acts centrally 
to increase appetite (Kokot and Ficek 1999). In a study on PCOS women, NPY levels were 
reported to be higher in obese and lean women with PCOS than in BMI-comparable control 
women (Baranowska et al. 1999). NPY has also been shown to augment the population of LH 
and of GnRH secreting fibers (Subdehar et al. 2005), while diminished NPY secretions have 
been linked with a lower surge-amplitude of LH and of GnRH (Sahu and Kalra 1998). It is 
possible that elevated levels of this neuropeptide in PCOS may also lead to high LH levels. NPY 
may therefore represent a link between reproductive dysfunction and obesity, and a fundamental 
contributing cause of PCOS. However, this hypothesis is purely speculative, as relatively few 
studies were found that have evaluated NPY levels in PCOS (and searching for additional studies 
is beyond the scope of this thesis). Future investigations focusing on the metabolic aspects of 
PCOS should consider evaluating NPY levels, as well as whether these levels correlate with BMI 
and with gonadotropic hormone levels (especially if such studies cannot be found in an extensive 
literature search on this particual subject). 
 
The Distribution of Adipose Tissue in PCOS 
Subcutaneous abdominal fat and visceral fat both contribute to the development of IR 
(Smith et al. 2001). Visceral fat furthermore creates a chronic low-grade inflammation (Carmina 
et al. 2007) and is a surrogate marker for ectopic fat accumulations (Huang et al. 2013), which 
are responsible for many of the harmful effects of obesity (Fabbrini et al. 2009, Klöting et al. 
2010). Many studies, based on anthropometric measures such as the waist-to-hip (WHR) ratio, 
suggest that there is a tendency in PCOS towards the accumulation of fat in these harmful areas 
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such as the abdominal visceral region. It is known that fat distribution in the abdominal area is 
associated with more adverse metabolic profiles in PCOS (Manneras-Holm et al. 2011, Moran 
and Teed 2009). However, there is debate whether abdominal fat storage occurs more in PCOS 
than in weight-matched controls. Several studies quantifying abdominal subcutaneous and 
visceral adipose tissue by MRI (Barber et al. 2008, Manneras-Holm et al. 2011), CT 
(Yalamanchi et al. 2012) and DEXA (which only quantifies total central abdominal fat) (Good et 
al. 1999) found no difference in the volume of total abdominal fat or visceral fat between PCOS 
women and BMI-matched controls. However, in other studies, MRI (Huang et al. 2013) showed 
an increase in visceral and subcutaneous abdominal fat and DEXA (Kirchengast and Huber 
2001) showed an increase in the proportion of upper body fat in PCOS women compared to 
BMI-matched controls. The different results may depend on the small number of patients and 
controls and may also be related to the degree of obesity (Huang et al. 2013). Studies in which 
the majority (Carmina et al. 2007, Huang et al. 2013, Puder et al. 2005) or all (Kirchengast and 
Huber 2001) of the women were non-obese have reported a higher quantity of central abdominal 
fat in PCOS women than in BMI-matched controls. Results from a more highly powered study 
with over 200 patients and controls evaluated by DEXA support the suggestion that the 
disparities reported by different authors are related to the degree of obesity (Carmina et al. 2007). 
When the 220 subjects from the study were stratified according to BMI into obese and non-obese 
sub-groups, there was no difference in the quantity of central abdominal fat between obese 
PCOS women and obese control women, but when limiting the comparison to the non-obese 
women, the quantity of central abdominal fat was higher in non-obese PCOS women compared 
to the quantity in non-obese control women (Carmina et al. 2007). These observations 
demonstrate that when obesity is present, most subjects display abdominal obesity, independent 
of being afflicted with PCOS or not (Carmina et al. 2007). However, when obesity is not present, 
PCOS patients stock a higher portion of their total adiposity in the abdominal region than do 
BMI-comparable controls (Carmina et al. 2007). Abdominal adiposity may therefore be a risk 
factor in non-obese PCOS women that confers on them adverse metabolic profiles compared to 
their BMI-matched non-PCOS counterparts (Carmina et al. 2007). Studies report that the 
quantity of central abdominal fat positively correlates with the degree of IR in non-obese PCOS 
women (Carmina et al. 2007) and to the level of inflammatory markers (Puder et al. 2005). 
DEXA accurately quantifies fat in different regions, is not operator dependent and, unlike MRI, 
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can be used on large populations (Carmina et al, 2007). DEXA may therefore be a useful 
screening tool for non-obese PCOS women susceptible to central abdominal fat accumulation, 
and, hence, to the adverse metabolic complications associated with centripetal fat distribution 
(Carmina et al. 2011, Moran and Teed 2009). 
Adipokines 
The increased incidence and severity of cardiovascular risk factors and of metabolic 
disturbances in PCOS may be in part related to the abnormal production and release of 
adipokines and inflammatory factors by adipose tissue (Randeva et al. 2012). Although 
traditionally regarded as a storage organ, emerging evidence also strongly suggests that adipose 
tissue is an endocrine organ (Randeva et al. 2012), whose altered function may produce 
widespread cardiometabolic disturbances in PCOS. As alluded to earlier, it is believed that 
dysregulated adipocyte function and obesity play a pathophysiological role in PCOS (Faulds et 
al. 2005, Teede et al. 2010). 
Leptin 
Leptin, a protein secreted by adipocytes, suppresses an individual’s appetite and 
promotes energy expenditure (Kumar and Clark 2009). Serum leptin levels are elevated in obese 
patients, who are considered leptin resistant (Kumar and Clark 2009). 
Hyperleptinemia: Data from a study by Wallace et al. with over 1000 study participants 
suggested that hyperleptinemia is an independent, positive risk factor for cardiovascular disease 
(Wallace et al. 2001).  Knudson et al. showed that leptin receptors are present on coronary 
endothelium (Knudson et al. 2005). Excessive leptin may cause coronary endothelial dysfunction 
(Knudson et al. 2005) followed by the subsequent development of atherosclerosis (Reilly et al. 
2004). 
Leptin and reproductive disorders:: Some authors have suggested that leptin plays a role in 
reproduction. Leptin deficiency in mice, induced by the ob/ob genetic mutation (Barash et al. 
1996) or by starvation (Ahima et al. 1996), produces amenorrhea and hypogonadism, whereas 
leptin administration to such mice restores menstruation and treats hypogonadism (Barash et al. 
1996, Ahima et al. 1996). Although leptin deficient mice have low levels of LH and FSH, leptin 
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levels in most studies of PCOS women did not correlate with LH or FSH levels (Mantzoros et al. 
1997, Hahn et al. 2006, Rouru et al. 1997, Telli et al. 2002). 
Leptin levels in PCOS: These findings, including the possible effects of leptin resistance on the 
pituitary-gonadal axis (Telli et al. 2002), have led authors to investigate the possible role of 
leptin in PCOS. Although some studies have found leptin levels to be elevated in PCOS women 
compared to controls (Brzechffa et al. 1996, Yildizhan et al. 2011), the general consensus 
reported by the majority of published studies is that there is no difference in circulating leptin 
levels in PCOS subjects in comparison to BMI-matched controls (Gennarelli et al. 1998, Hahn et 
al. 2006, Iuorno et al. 2007, Mantzoros et al. 1997, Pirwany et al. 2001, Rouru et al. 1997, 
Sepillian et al. 2006, Svendsen et al. 2012, Telli et al. 2002). The different results might be 
explained by differences in ethnicity, heterogeneity in criteria used to classify PCOS, and low 
number of PCOS subjects and controls (Chen et al. 2013, Telli et al. 2002). Furthermore, the 
studies by Brzechffa et al. and Yildizhan et al. did not match properly for BMI (Telli et al. 2002). 
Further investigation with more participants may be needed to more precisely elucidate the role 
of leptin in PCOS. 
In support that leptin levels do not differ between PCOS women and controls are two 
important studies. One of these is the study by Telli et al. which used uniform criteria 
(hyperandrogenism, oligomenorrhea and PCO on ultrasound) to recruit PCOS subjects and 
matched adequately for BMI. The second of these is the study by Hahn et al., which included 
over 200 participants, more than the other studies. Both of these studies found no differences in 
leptin levels in PCOS women in comparison to BMI-matched controls (Hahn et al. 2006, Telli et 
al. 2002). Furthermore, other studies report the levels of circulating leptin to be no different in 
ovulatory PCOS patients and in non-ovulatory ones (Carmina et al. 2009, Pirwany et al. 2001); 
the same finding applies between oligomenorrheic and amenorrheic PCOS women (Hahn et al. 
2006). 
Interestingly, Hahn et al. reported that despite similar levels of total leptin, PCOS women 
had lower levels of the soluble leptin receptor sOB-R and therefore higher levels of free 
biologically active leptin (Hahn et al. 2006). However, in a similar study, Sepilian et al. reported 
no differences in the level of sOB-R or free leptin index between PCOS women and controls 
(Sepilian et al. 2006). Results from a study of leptin levels and sOB-R levels in twins suggests 
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that BMI influences total leptin levels while genetic components regulate sOB-R levels (Hahn et 
al. 2006, Li et al. 2005), suggesting that genetic background may be responsible for lower sOB-R 
levels and higher free leptin levels in a subgroup of PCOS women (Hahn et al. 2006). However, 
given the differing and varied results among studies, further investigations are needed to 
elucidate the role of sOB-R in PCOS. 
Leptin and adiposity in PCOS:  Most studies report that adiposity, quantified by BMI, is the 
main correlative component and determinant of leptin levels in PCOS women (Gennarelli et al. 
1998, Hahn et al. 2006, Iuorno et al. 2007, Mantzoros et al. 1997, Pirwany et al. 2001, Rouru et 
al. 1997, Sepillian et al. 2006, Svendsen et al. 2012, Telli et al. 2002). Leptin mRNA expression 
in adipocytes did not differ between PCOS women and BMI-matched controls (Svendsen et al. 
2012), providing further evidence that obesity, rather than PCOS per se, affects leptin production 
and circulating levels. 
Leptin, androgens and PCOS: After adjustment for BMI, some authors report that leptin levels 
do correlate minimally with the free androgen index (Geneneralli et al. 1998, Hahn et al. 2006, 
Laughlin et al. 1997, Pirwany et al. 2001), but nevertheless do not differ between visibly hirsute 
and non-hirsute women with PCOS (Gennarelli et al. 1998).  
Leptin and insulin levels in PCOS: Most studies also addressing leptin and insulin report that 
after adjustment for BMI, leptin levels in PCOS women do not correlate with the chronic insulin 
levels (Genneralli et al. 1998, Laughlin et al. 1997, Mantzoros et al. 1997, Sepilian et al. 2006, 
Svendsen et al. 2012), while others report that leptin levels in PCOS women did correlate with 
measures of insulin resistance (Hahn et al. 2006, Yildizhan et al. 2011). However, in further 
support of findings that negate a significant correlation between insulin resistance and leptin 
levels, treatment of chronically hyperinulinemic insulin resistant PCOS women with the 
thiazolidinediones troglitazone (Manntzoros et al. 1997) or rosiglatazone (Sepilian et al. 2006) 
was shown to lower insulin levels but did not alter leptin levels in these patients. 
Adiponectin 
Adiponectin, which is secreted exclusively by adipose tissue, exerts insulin sensitizing 
actions both indirectly (Kadowaki et al. 2006) and directly by activating tyrosine 
phosphorylation of the skeletal muscle insulin receoptor (Stefan et al. 2002). Adiponectin levels 
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are reduced in insulin resistance states such as DM2 across all ethnic groups (Weyer et al. 2001). 
Low levels are also associated with a faster progression towards DM2 in at-risk individuals 
(Weyer et al. 2001) and with higher risk of CHD in women (Zyriax et al.2008). Low levels are 
also possibly associated with high LH/FSH ratios and impaired ovulation because adiponectin in 
normal levels reduces secretion of LH through AMPK phosphorylation without affecting FSH 
secretion (Lu et al. 2008). 
A meta-analysis has demonstrated that adiponectin levels are lower in PCOS women than 
in control women of comparable BMI (Toulis et al. 2009). A more recent meta-analysis has 
indicated that the T45G polymorphism in the adiponectin gene is associated with PCOS (Gao et 
al. 2012). Although few studies exist focusing on high molecular weight adiponectin and the 
earlier meta-analysis did not specifically evaluate levels of high molecular weight (HMW) 
adiponectin (Toulis et al.2008), which is considered to be a more potent mediator of insulin 
sensitivity (Pajvani et al. 2004), it has been reported that levels of HMW adiponectin and the 
ratio of HMW adiponectin to total adiponectin are both lower in PCOS women than in age and 
BMI comparable controls (Wickham et al. 2011). 
Visfatin 
Visfatin is a cytokine secreted, among other cell types, by adipocytes (Fukuhara et al. 
2005). It stimulates glucose uptake by cells, thus inducing insulin-mimetic effects (Fukuhara et 
al. 2005). A meta-analysis established that plasma visfatin levels are significantly increased in 
subjects with obesity, DM2, metabolic syndrome and CVD (Chang et al 2011). Furthermore, in 
diabetics, serum visfatin levels increase with progressive β-cell deterioration (Lòpez-Bermejo et 
al. 2006). Haider et al demonstrated that insulin inhibited visfatin release from adipocytes in 
healthy subjects, suggesting that elevated visfatin levels may reflect insulin resistance (Haider et 
al. 2006). 
Given visfatin’s insulin-mimetic actions, some authors have suggested visfatin may be 
elevated to compensate for insulin resistance (Tan et al. 2006) and to prevent further resistance to 
insulin (Kowalska et al. 2007, Zahorska-Markiewicz et al. 2007). However, elevated visfatin 
levels may produce harmful effects. Rising visfatin levels correlate with the degree of endothelial 
dysfunction, quantified by the decline in flow mediated vasodilation and impaired renal 
clearance (Takebayashi et al. 2007). Visfatin activates nuclear transcription factor NF-kB in 
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vascular endothelial cells (Adya et al. 2008) and in lipid-laden macrophages of atherosclerotic 
lesions (Fan et al. 2011), culminating in the activation of metalloproteinase 2 (Adya et al. 2008) 
and metalloproteinase -9 (Fan et al. 2011, Dahl et al. 2007), leading to vascular inflammation 
and plaque destabilization, respectively. 
In patients undergoing carotid endarterectomy or percutaneous coronary interventions, 
visfatin expression is higher in the atherosclerotic lesions of symptomatic patients than in the 
lesions of unsymptomatic patients, further emphasizing the role of this adipokine in plaque 
destabilization and acute cardiovascular events (Dahl et al. 2007). Likewise, elevated visfatin 
levels in PCOS may also signal heightened cardiovascular risk in certain women with this 
syndrome, particularly in those with insulin resistance. 
Given its associations to insulin resistance and vascular inflammation, several studies 
have undertaken to elucidate the role of visfatin in PCOS. Higher levels of serum visfatin and 
visfatin mRNA in adipocytes have been reported in PCOS women compared to BMI-matched 
controls (Chan et al. 2007, Kowalska et al. 2007, Ozkaya et al. 2010, Panidis et al. 2008, Tan et 
al. 2006).  Serum visfatin levels were found to correlated with BMI (Tan et al. 2006, Chan et al. 
2007), insulin resistance (Kowalska et al. 2007, Seow et al. 2011, Tan et al. 2006), free androgen 
index (Kowalska et al. 2007) and LH levels (Panidis et al. 2008). 
It has been observed that metformin treatment for 3 months lowered visfatin levels 
(Ozkaya et al. 2010). However, the investigations demonstrated many inter-study variations in 
parameters such as BMI, IR, FAI and LH that significantly correlated with visfatin levels in 
some studies but not in others. These variations may be attributed to the small number of 
participants, less than 30 PCOS women in all but one (Kowalska et al. 2010) of these 
investigations, and to interracial variations in the phenotypic expression of PCOS (Tan et al. 
2006). 
More recent studies have reported no differences in visfatin levels between PCOS women 
and controls (Lajunen et al. 2012, Olszanecka-Glinianowicz et al. 2012), therefore necessitating 
further inquiries with more participants to clarify the role of this adipokine in PCOS. 
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Chemerin 
Chemerin is a chemotactic protein secreted by adipocytes (Bozaoglu et al. 2007, Sell et 
al. 2009) that is necessary for adipocyte differenciation (Roh et al. 2007). It is able to attract 
macrophages, which express the chemerin receptor CMKLR1 (chemokine-like receptor 1) 
(Zabel et al. 2005). In view of its chemo-attractant properties, this adipokine may be one factor 
underlying the link between obesity and chronic inflammation (Zabel et al. 2005). Chemerin also 
induces insulin resistance in peripheral tissues such as skeletal muscle by activation of ERK-1/2 
and NF-kB pathways, culminating in inhibited cellular glucose uptake (Sell et al. 2009). Insulin 
stimulates chemerin secretion, promoting a vicious circle increasing insulin resistance (Tan et al. 
2009). This protein is thought to possibly present a link between obesity and diabetes (Sell et al. 
2009). Serum chemerin levels have been found to correlate with BMI (Bozaoglu et al. 2007, Sell 
et al. 2009), WHR (Boazoglu et al. 2007, Sell et al. 2009), triglycerides (Boazoglu et al. 2007), 
elevated blood pressure (Boazoglu et al. 2007), and adipocyte volume (Sell et al. 2009). 
Adipocyte volume has been found to be higher in PCOS patients, even in lean PCOS patients 
when compared to BMI-matched controls (Faulds et al. 2003). Chemerin levels in PCOS are of 
interest, as this may be one of the factors underlying insulin resistance so common in PCOS. 
Chemerin is also implicated in inflammation, which may be responsible for vascular damage 
leading to CVD. Chemerin levels have been reported to be higher in obese PCOS women than in 
BMI and WHR matched controls (Guzel et al. 2014, Tan et al. 2009) as well as in lean PCOS 
women compared to BMI matched controls (Guzel et al. 2014).  Treatment of the PCOS patients 
with metformin for 6 months has lowered chemerin levels and improved insulin resistance, 
without changing BMI (Tan et al. 2009). 
 
Proinflammatory and Macrophage-Derived Factors 
 
This section presents a survey of macrophages and proinflammatory factors such as 
tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), Interleukin-6 (IL-6), Interleukin 
– 18 (IL-18) and white blood cells (WBC). 
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Macrophages 
Adipose tissue inflammation mediated by activated tissue macrophages (ATM) is a major 
pathway culminating in the development of obesity-related insulin resistance (Lumeng et al . 
2011, Wentworth et al. 2010). CD11c is a marker specific to these ATMs that infiltrate adipose 
tissue in obese individuals and secrete cytokines such as TNF- and IL-6, both associated with 
insulin resistance. In contrast, the markers CD206, CD14 and CD163 are expressed by less 
inflammatory macrophages (Wentworth et al. 2010). CD11c-expressing macrophages cluster 
around dead adipocytes, forming histologically defined crown-like structures (CLS) (Wentworth 
et al. 2010). The density of CLS has been found to correlate with the degree of insulin resistance 
and obesity (Wentworth et al. 2010). CD11c and CLS density is significantly higher in lean and 
obese PCOS women than in BMI-comparable non-PCOS controls (Huang et al. 2013). The 
observation that CD11c macrophages and CLS occur more frequently in obese men than in obese 
women has lead to the suggestion that the increase observed in lean and obese PCOS women is 
likely a result of hyperandrogenism (Huang et al. 2013). CD11c adipose tissue infiltration and 
CLS may be an early change in lean hyperandrogenic PCOS women leading to the development 
of insulin resistance in this group (Huang et al. 2013) that is comparable to the insulin resistance 
in obese controls (Dunaif et al. 1989). 
TNF-α 
TNF- α plays a role in the pathogenesis of insulin resistance (Hotamisligil et al. 1995). It 
inhibits tyrosine phophorylation of the insulin receptor and of IRS-1 in muscle and fat cells 
(Hotamisligil et al. 1995), and has also been shown to down-regulate the expression of the 
GLUT4 transporter necessary for cellular entry of glucose (Stephens and Pekala 1991). Serum 
levels of TNF- α are elevated in both obesity and DM2 (Hotamisligil et al. 1995). 
Studies report that TNF- α  levels in PCOS correlate with BMI (Escobar-Morreale et al. 
2003a, Gonzalez et al. 1999, Puder et al. 2005, Samy et al. 2009) and that circulating TNF- α 
levels are elevated in both non-obese (Gonzalez et al. 1999, Sayin et al. 2003) and obese (Samy 
et al. 2009) PCOS women when compared with BMI-matched controls. However, in other 
studies, these differences in the levels of TNF- α between PCOS women and controls diminished 
after adjusting for BMI and abdominal adiposity (Escobar-Morreale et al. 2003a, Puder et al. 
2005), thus questioning whether TNF- α elevations are related to PCOS or are a function of 
excess adiposity. A meta-analysis found no significant difference in TNF- α levels between 
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PCOS subjects and BMI-matched controls (Escobar-Morreale et al. 2011). However, the authors 
caution against over-interpretation of these results, as their study also revealed evidence of a 
publication bias favoring publication of studies that underestimate the differences in TNF- α 
levels between PCOS women and controls (Escobar-Morreale et al. 2011). An important 
difference between PCOS and control subjects may be the lie in the TNF-α receptor (Peral et al. 
2002). Most of the metabolic effects of TNF-α are mediated through the TNF-α receptor 2 (Peral 
et al. 2002).  Although TNF-α receptor 2 levels were increased in obesity, no differences in 
levels were observed between PCOS women and controls (Peral et al. 2002). However, a the 
methionine 196 arginine polymorphism in exon 6 of the gene encoding the TNF-α receptor 2 was 
reported to be significantly more frequent in women with PCOS than in controls, suggesting that 
TNF-α plays a role in the development of metabolic pathologies in PCOS, and that this might be 
related to a structural change in the TNF-α receptor that confers a more responsive phenotype 
rather than to circulating TNF-α levels (Peral et al. 2002). Authors agree that larger and more 
highly powered studies are needed to clarify the role of TNF-α in PCOS (Escobar-Morreale et al. 
2011, Peral et al. 2002). 
CRP 
CRP has been proven to be a strong independent predictor of cardiovascular events in 
healthy asymptomatic as well as symptomatic women in the general population (Danesh et al. 
2004, Ridker et al. 2000). Obesity is associated with elevations in CRP (Yudkin et al. 1999).A 
meta-analysis of 26 studies matching carefully for BMI revealed that CRP is elevated in PCOS 
independently of obesity (Escobar-Morreale et al. 2011). This elevation of CRP in PCOS is more 
pronounced when obesity is present, further heightening the risk of cardiovascular events in this 
group of women (Escobar-Morreale et al. 2011). However, the authors caution against over 
attributing increased cardiovascular risk to PCOS per se because after adjusting for BMI, the 
elevation in CRP attributable to PCOS is relatively small (Escobar-Morreale et al. 2011). 
Interleukin-6 
Interleukin-6 (IL-6) is released by mononuclear leucocytes and adipose tissue (Escobar-
Morreale et al. 2011), with levels being elevated in obesity (Escobar-Morreale et al. 2011). It 
directly stimulates hepatic CRP synthesis (Escobar-Morreale et al. 2011). Although IL-6 
elevations have been reported in lean and obese PCOS women in relation to BMI comparable 
controls (Escobar-Morreale et al. 2011), a recent meta-analysis proved no significant difference 
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in circulating IL-6 levels between PCOS women and BMI-matched controls (Escobar-Morreale 
et al. 2011), suggesting that elevated IL-6 in PCOS is primarily related to obesity. 
However, a promoter region polymorphism (G/C) at position -174 of the gene encoding 
IL-6 has been found to be strongly associated with DM2 in the Caucasian population (Vozarova 
et al. 2003). This same polymorphism has been reported to occur more frequently in PCOS 
patients (Erdogan et al. 2008, Villuendas et al. 2002). Furthermore, a certain microsatellite CA-
repeat polymorphism in the locus encoding the α-subunit of the IL-6 receptor is associated with 
obesity, while the Arg148 allele in the region encoding the gp130 subunit of the IL-6 receptor 
gene is more common in normoandrogenic subjects than hyperandrogenic ones (Escobar-
Morreale et al. 2003b). These observations suggest that genetically determined hypersignaling 
defects in the IL-6 receptor, rather than only circulating IL-6 levels, may be implicated in the 
pathogenesis of metabolic hyperandrogenic disorders such as PCOS (Escobar-Morreale et al. 
2003b). However, relatively little is known about this field and authors agree that larger studies 
are needed (Escobar-Morreale et al. 2003b, Escobar-Morreale et al. 2011). 
Other inflammatory mediators - IL-18 and WBC  
Studies on IL-18 and MNC are insufficient in numbers to perform a meta-analysis, but 
the limited existing evidence suggests that elevations of IL-18 and WBC in PCOS are 
independent of obesity (Escobar-Morreale et al. 2011). 
Dyslipidemia 
 
Dyslipidemia is the most common metabolic abnormality in PCOS (Hoffman and 
Ehrmann 2008, Randeva et al. 2012), and polycystic ovary syndrome is the leading cause of 
dyslipidemia in reproductive-age women (Sam and Dunaif 2003). Observations of PCOS 
affected women and their relatives have shown that the probability of developing dyslipidemia is 
1.8 fold larger in the PCOS individuals (Randeva et al. 2012). Overall, studies of PCOS patients 
report slightly decreased levels of cardioprotective HDL-C, with slightly elevated levels of TG, 
VLDL-C and LDL-C (Hoffman and Ehrmann 2008, Randeva et al. 2012). PCOS women display 
the lipid profile observed in insulin resistant states such as DM2, and characterized specifically 
by elevated TG and lowered HDL-C (Legro et al. 2001, Randeva et al. 2012). The main 
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determinant of heart disease risk is the total cholesterol (TC) to HDL-C ratio (Wild et al. 2010). 
This ratio is also slightly elevated in PCOS patients (Randeva et al. 2012). 
Elevated LDL-C (Graf et al. 1990, Legro et al. 2001, Sam et al. 2005, Talbot et al. 1998) 
and VLDL-C (Graf et al 1990) in PCOS are further elevated when excess adiposity is present, 
but, as confirmed by a recent meta-analysis, the higher levels occur in PCOS independently of 
obesity (Wild et al. 2011). Elevated LDL-C levels are linked with hyperandrogenemia (Graf et 
al. 1990, Sam et al. 2005, Wild et al. 1985). It is unclear whether hyperandrogenemia and 
elevated LDL-C have a causal relationship or whether these are closely related genetic traits 
inherited together (Sam et al. 2005). 
Although LDL-C and VLDL-C are elevated in PCOS independently of obesity, obesity is 
thought to be the major determining factor for elevations in TG levels and for the reduction of 
HDL-C levels that are observed in PCOS (Joharatnam 2011, Legro et al. 2001, Sam et al. 2005, 
Wild et al. 2011). In a study comparing lipid profiles between PCOS probands, their sisters with 
and without PCO morphology on ultrasound, and controls, the elevated TG levels and reduced 
HDL-C levels in probands relative to the other groups disappeared after controlling for BMI 
(Joharatnam et al. 2011), suggesting that BMI is the predominant determinant of TG and HDL-C 
levels in PCOS (Joharatnam et al. 2011), both of which are strong independent risk factors for 
death from cardiovascular disease (Bass et al. 1993). However, after adjustment for BMI, age, 
and centripetal obesity in another large study of PCOS women, HDL-C levels still remained 
significantly lower in PCOS women when compared to controls, though only slightly so. This 
indicates that factors other than BMI and centripetal obesity are contributors to the lowering of 
HDL-C levels in PCOS women, although, of course, BMI is observably a significant determinant 
of lipid profiles (Glueck et al. 2009). 
In a study which did not control for diet, HDL-C levels were unexpectedly higher in 
obese PCOS women than in obese controls (Legro et al. 2001). This inconsistency signals that in 
addition to BMI (Joharatnam et al. 2011), other factors such as age, ethnicity, genetic influences 
and environment also modulate lipid profiles of women with PCOS (Carmina et al. 2006a, Legro 
et al. 2001, Essah et al. 2008, Talbot et al. 1998). The importance of environmental (diet, activity 
level) and genetic contributions to dyslipidemia is evidenced by the fact that TG elevations in 
24 
 
American PCOS women compared to Italian PCOS women persist even after controlling for 
BMI (Carmina et al. 2006, Essah et al. 2008). 
Even PCOS women with normal lipid profiles may be at increased risk for cardiovascular 
events. This is because significantly higher levels of lipoprotein-a and a higher proportion of 
small, dense LDL have been found in PCOS patients compared to controls (Berneis et al. 2009), 
although TC and total LDL-C levels did not differ between PCOS and control women (Berneis et 
al. 2009). This similarity in TC and total LDL-C levels makes the PCOS women appear to have 
normal lipid profiles. Such PCOS women are at higher risk for cardiovascular events, because 
certain lipoproteins, such as lipoprotein-a and small, dense LDL-C, are more atherogenic 
(Berneis et al. 2009).  
Another atherogenic shift in PCOS is the lipid-to-protein ratio of HDL-C particles. The 
lipid-to-protein ratio in an HDL-C particle reflects the capacity of the particle to remove 
cholesterol from tissues (Rajkhiova et al. 1997). A reduction of this ratio signals a decreased or 
impaired capacity to remove cholesterol and prevent atherosclerosis (Rajkhiova et al. 1997).  
In one study, the lipid-to-protein ratio in the HDL-C was found to be lower in obese 
PCOS women than in obese women without PCOS (Rajkhiova et al. 1997). The latter finding 
signals a drop in the anti-atherogenic properties of HDL-C of PCOS women (Rajkhiova et al. 
1997).  
Despite slight changes in lipid profiles in PCOS, most women with PCOS are young and 
have normal blood pressure, and hence do not qualify for primary prevention of cardiovascular 
disease (Randeva et al. 2012). Nevertheless, it is suggested to perform at least one measurement 
of lipid profiles in PCOS in conjunction with an assessment for other cardiovascular risk factors 
such as smoking and family history of CVD (Randeva et al. 2012). 
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Traditional and novel cardiovascular risk factors in PCOS 
 
Traditional Cardiovascular Disease Risks Factors in PCOS 
Traditional risk factors for cardiovascular disease, such as IGT, DM2, dyslipidemia, 
obesity, and elevated blood pressure, are more prevalent in women with PCOS than in control 
women of similar age (Wild et al. 2010). 
Markers of Atherosclerosis 
Calcification of the coronary arteries assessed by electron beam computed tomography 
correlates with the degree of atherosclerosis found on histopathological exam and was found to 
predict the incidence of cardiovascular events in asymptomatic women (Arad et al. 2000). The 
prevalence and extent of coronary artery calcification (CAC) were found by several studies to be 
higher in both younger (aged 30 to 45 years) and older (aged over 40 years) women with PCOS 
than in controls, independently of age and BMI (Christian et al. 2003, Shroff et al. 2007, Talbott 
et al. 2004).  It has been suggested that the reported increase in CAC among PCOS women is 
related to the parameters that were different in PCOS women in relation to the control women in 
the studies -  increased LDL-C (Christian, et al. 2003, Talbot et al. 2004), lower HDL-C (Talbot 
et al. 2004) and hyperinsulinemia (Talbot et al. 2004). Among the women with PCOS, BMI was 
a significant predictor of whether the women would have CAC (Christian et al. 2003, Talbott et 
al. 2004, Shroff et al. 2007), leading to the suggestion that obese women with PCOS should be 
targeted for aggressive treatment and prevention of cardiovascular disease (Christian et al. 2003, 
Shroff et al. 2007). Talbott et al. also reported higher prevalence and extent of aortic calcification 
(AC) in women with PCOS (Talbott et al. 2004).  The investigators of the latter study found that 
total testosterone was an independent risk factor for greater AC (Talbott et al. 2004). In animal 
models, testosterone exacerbated atherosclerosis in female monkeys but conferred a protective 
effect in males (Talbott et al. 2004). Similarly, a large study reported that men with the highest 
total testosterone levels had a reduced risk of AC, but conversely, women with elevated 
testosterone levels had the highest risk for CAC (Hak et al. 2002, Talbott et al. 2004), leading 
authors to suggest that the aorta in women may be more sensitive to the effects of endogenous 
testosterone (Hak et al. 2002, Talbott et al. 2004). 
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Increased intima-media wall thickness (IMT) is an early marker of atherosclerosis 
(Lorenz et al. 2007). Increased carotid intima-media wall thickness (CIMT) is a strong 
independent predictor of the occurrence of major cardiovascular events later in life (Lorenz et al. 
2007). Higher CIMT has been reported in both younger (age 20 to 35 years) (Carmina et al. 
2006b, Luque-Ramirez et al. 2007) and older (over 45 years) (Talbott et al. 2004) patients with 
PCOS in comparison to controls of similar age and BMI. A recent meta-analysis indicated that 
women with PCOS had a 0.072 to 0.084 mm higher CIMT compared to controls (Meyer et al. 
2012). Every 0.10 mm increase in CIMT has been estimated to increase the risk of a myocardial 
infarction (MI) by 15% and the risk of stroke by18% (Meyer et al. 2012). The increase in CIMT 
in PCOS relative to controls of comparable age and BMI has been associated in different studies 
to higher levels of insulin (Carmina et al. 2006b), hyperandrogenism (Luquez-Ramirez et al. 
2007), Il-18 (Meyer et al. 2012), LDL-C (Meyer et al. 2012), and abdominal obesity (Meyer et 
al. 2012), although the contribution of each of these factors to increased CIMT in PCOS has not 
been systematically evaluated (Meyer et al. 2012). However, CIMT increases with age in PCOS, 
as in the general population (Meyer et al. 2012). 
Vascular Endothelial Dysfunction 
Several studies have demonstrated decreased brachial artery flow mediated dilation 
(FMD), a marker of endothelial function, in young normal weight, overweight and obese women 
with PCOS compared to body mass matched controls (Carmina et al. 2006a, Orio et al. 2004a). 
The decreased FMD was observed even in normal weight PCOS women who were also 
normotensive and had normal lipid profiles (Orio et al. 2004a) and who therefore lacked many of 
the traditional cardiovascular risk factors (Orio et al. 2004a). It has been suggested that elevated 
androgen levels in the PCOS women relative to controls contributed to the observed decline in 
endothelial function (Carmina et al. 2006b). When obese PCOS and control women of similar 
age, BMI, LDL-C and TC levels received intra femoral artery infusions of the endothelial-
dependent vasodilator methacholine chloride (MCh), the leg blood flow was 50% less in the 
PCOS women compared to the controls, suggesting impaired nitric oxide (NO) production in the 
endothelial cells of PCOS women (Paradisi et al. 2001). The degree of decrease in leg blood flow 
was strongly associated with free testosterone levels (Pardisi et al. 2001). This, in conjunction 
with the observation that androgen deprivation in men has enhanced endothelial-dependent 
vasodilation (Herman et al. 1997), has led to the suggestion that elevated androgen levels in 
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PCOS women may be a major contributor to endothelial dysfunction and macrovascular disease 
(Paradisi et al. 2001). 
Several molecules implicated in endothelial dysfunction have been linked to PCOS. A 
recent meta-analysis indicated that homocysteine, a mediator of endothelial injury, is in higher 
levels in PCOS women than in controls of similar age and BMI (Murri et al. 2013). The same 
study also demonstrated that levels of asymmetric dimethylarginine (ADMA), a competitive 
inhibitor of endothelial NO synthase and an independent risk marker for cardiovascular 
morbidity and mortality (McDowell and Lang 2000), are higher in PCOS women than in age and 
BMI matched controls (Murri et al. 2013). Several studies have found that in comparison to age- 
and BMI- comparable control women, PCOS women also exhibit elevated levels endothelin-1 
(Caramina et al. 2006b, Diamanti-Kandarakis 2012), a by-product of endothelial damage and a 
potent vasoconstrictor (Carmina et al. 2006b). Plasminogen activator inhibitor-1, which inhibits 
fibrinolysis and in higher levels predisposes to accelerated development of atherosclerosis 
(DeLoughrey 1999), has been shown to be elevated in normal weight young PCOS women 
relative to controls (Yildiz et al. 2002). 
Cardiac Dysfunction 
Studies report that compared to age and BMI matched controls, young PCOS women 
have increased left ventricular mass index (LVMi) (Orio et al. 2004b), a predictor of CVD 
morbidity and mortality (Randeva et al. 2012), and decreased diastolic filling (Orio et al. 2004b, 
Tiras et al. 1999). Both of these abnormalities occur independently of excess weight, presenting 
in lean as well as overweight and obese PCOS patients. Additionally, decreased left ventricular 
ejection fraction has been reported in young overweight and obese women with PCOS compared 
to controls (Orio et al. 2004b). 
The risk of cardiovascular events in PCOS 
There are conflicting results from studies evaluating the risk of cardiovascular events in 
PCOS. 
A 49-year follow-up study of 786 women diagnosed with PCOS based only on ovarian 
wedge section found that the risk of fatal cardiovascular events was no different between PCOS 
women and controls (Pierpoint et al. 1998). Similarly, a retrospective study of 319 women 
diagnosed with PCOS based on more stringent criteria (an/oligo-ovulation and 
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hyperandrogenism) reported that there was no difference in cardiovascular mortality risks 
between PCOS women and age matched-controls (Wild et al. 2000), although the PCOS women 
demonstrated a higher risk for non-fatal cerebrovascular events, even after adjustment for BMI 
(Wild et al. 2000). 
Another investigation followed 82,439 women aged 20-35 for 14 years (Solomon et al. 
2002). Compared with women reporting a history of regular menses, women reporting a history 
of very irregular menses had a significantly higher risk for nonfatal and fatal cardiovascular 
disease, even after adjustment for BMI, age, menopausal status, and smoking (Solomon et al. 
2002). Although these women were not diagnosed with PCOS, it is estimated that 80-90% of 
women reporting menstrual irregularity have PCOS (Randeva et al. 2012). Furthermore, a recent 
meta-analysis indicated a 2-fold increased risk of coronary heart disease (CHD) and stroke for 
patients with PCOS relative to women without PCOS (de Groot et al. 2011). The meta-analysis 
found that there is a 55% increase in the risk for CHD and stroke in PCOS women using only 
studies that adjusted for BMI, showing that BMI is not the sole cause of increased risk for 
cardiovascular events in women with PCOS (de Groot et al. 2011). 
The risk of cardiovascular events also appears to be higher in postmenopausal women 
with a history of PCOS than those without. The Women’s Ischemia Syndrome Evaluation study 
reported that the cumulative 5-year event free survival for women without a history of PCOS is 
88.4%, and only 78.9% for those with a premenopausal history of PCOS (Shaw et al. 2008). 
A retrospective study found similar results. The study evaluated the incidence of CV 
events (MI, angina, heart failure, stroke, CV death) in a cohort of 2300 PCOS women between 
1988 and 2009 (Mani et al. 2013). Overall, CV events were not any more prevalent in the cohort 
than in the local female population (Mani et al. 2013). However, when the cohort was stratified 
by age and comparisons were limited to age-similar groups in the local female population, PCOS 
showed an association with CV events within each age group (Mani et al. 2013). The age-
specific prevalence of CV events was significantly higher in PCOS patients over 45 compared 
with the local female population, with odds ratio as high as 12.88 in women over 65 with a pre-
menopausal history of PCOS (Mani et al. 2013). Factors in the cohort associated with an 
increased risk of CV events were age, hypertension, obesity, smoking and having DM2 (Mani et 
al. 2013). 
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Management 
This section reviews the therapies used to manage the cardiometabolic disturbances 
observed in PCOS. The treatment of other manifestations of PCOS, such as hirsutism and 
anovulation, can itself be a cause of cardiometabolic risks (as will be shown later in the sub-
section on oral contraceptive pills (OCPs) and in the sub-section on anti-androgenic therapies).  
Therefore, this section also discusses the cardiometabolic risks that have manifested during 
management with OCPs and anti-androgenic agents.  Factors influencing whether or not 
metabolic side effects will arise during OCP use are also discussed so that such side effects can 
be minimized. 
Lifestyle Interventions 
 
Lifestyle change is the first line of treatment for most overweight and obese women with 
PCOS (Teede et al. 2010). Additionally, normal weight PCOS women are advised to prevent 
excessive weight gain (Teede et al. 2010). A weight loss of 5-10% through lifestyle modification 
restores ovulation in many obese and overweight women with PCOS (Lefebvre et al. 1997, 
Huber 1999), reduces androgen levels, improves hirsutism (Levebre et al. 1997) and improves IR 
(Huber et al. 1999). Although current recommendations propose an energy reduced diet 
consisting of low fat, moderate protein and high carbohydrate content with low glycemic 
indexes, there is a shift towards increasing the protein proportion and lowering the carbohydrate 
one, as this approach has been shown to lead to more fat loss (Mikkelsen et al. 2000, Kasim-
Karakas et al. 2009) and improve lipid profiles in PCOS women more than carbohydrate-based 
diets (Kasim-Karakas et al. 2009). Even moderate exercise alone with no change in diet, 
although not resulting in any weight loss, has been shown to reduce IR and improve lipid profiles 
of PCOS women (Brown et al. 2013). 
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Pharmacological Management 
 
Insulin-sensitizing drugs 
 
Thiazolidinediones 
Studies of the use of thiazolidinedione drugs in PCOS demonstrate conflicting results. A 
systematic Cochrane Review reported that the use of rosiglitazone in PCOS women improves IR, 
endothelial function and lowers androgen concentrations (Lord et al. 2003a). However, in a 
randomized control trial among non-obese PCOS women with study groups consisting of 
placebo, metformin alone, rosiglitazone alone and combination metformin and rosiglitazone 
therapy, it was observed that although rosiglitazone alone lowered androgen levels, it lead to 
weight gain and did not improve insulin resistance (Baillargeon et al. 2004). In the latter study, 
insulin resistance improved only with metformin therapy or with combination metformin-
rosiglitazone therapy (Baillargeon et al. 2004). Furthermore, thiazolidinediones exacerbate the 
risk of bone fracture, exacerbate pre-existing congestive heart disease (CHD), and the 
thiazolidinedione troglitazone was pulled off of the market because of hepatocellular toxicity 
(Wild et al. 2010). Therefore, thiazolidinedione use is limited (Wild et al. 2010). 
Metformin 
Metformin is incontrovertibly known to lower IR and increase insulin-mediated glucose 
disposal (Bargiota and Diamant-Kandarakis 2012, Ibáñez et al. 2000, Lord et al. 2003a, Moghetti 
et al. 2000, Pasquali et al. 2000, Santana et al. 2004). One study of PCOS women taking 
metformin demonstrated a reduction of the annual NGT to IGT conversion rate in PCOS women 
by 11-fold (from 16% to 1.4%) and an increase in the annual IGT to NGT reversion rate from 
2.25 % (Legro et al. 2005) to 11% (Sharma et al. 2007). A meta-analysis demonstrated that 
metformin reduces the onset of DM2 in at risk individuals, including in women with PCOS, by 
40% (Salpeter et al. 2008). Other beneficial effects in PCOS after the initiation of metformin 
therapy include reductions of CRP (Morin-Papunen et al. 2003a) and IMT (Orio et al. 2003a), 
and an enhancement of FMD (Diamanti-Kandarakis et al. 2005). 
However, metformin does not always effectively improve IGT (Bargiota and Diamanti-
Kandarakis 2012). A study that followed a large number of women with PCOS and under 
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metformin treatment showed that the effectiveness of metformin in preventing progression to 
diabetes is a function of baseline glucose levels and insulin sensitivity (Glueck et al. 2008).These 
observations highlight the importance of early intervention. Metformin is also not as effective in 
morbidly obese patients (Bargiota and Diamanti-Kandarakis 2012). If a patient is morbidly 
obese, or if early intervention was not undertaken and the impairment of glucose metabolism is 
long-existing, metformin therapy will improve IGT, if at all, only at higher doses (Bargiota and 
Diamanti-Kandarakis 2012). However, the dangers of high doses preclude this practice from 
being implemented. These observations point out the need for development of ways to manage 
this group of resistant patients.  
Metformin use in obese PCOS women not undergoing lifestyle changes has been shown 
to induce no (Moghetti et al. 2000) or only minimal (2.7 kg or 2.9%) (Nieuwenhuis-Ruifro et al. 
2009) weight loss. RCTs have shown that the combination of metformin and lifestyle changes in 
obese PCOS women produce slightly more weight loss and a significantly higher reduction in 
visceral fat than lifestyle changes only (Gambineri et al. 2006, Pasquali et al. 2000), with the 
effect of metformin on inducing weight loss being dose dependent (Harbourne et al. 2005). 
Metformin may reduce appetite in obese PCOS women by lowering neuropeptide Y levels 
(Orbetzova et al. 2011). The Androgen Excess Society (AES) recommends the introduction of 
metformin therapy in obese women with PCOS in whom lifestyle intervention did not 
appreciably improve IGT (Wild et al. 2010). The AES also recommends metformin therapy in 
PCOS women with IGT who are in the normal weight range and in whom weight loss would 
therefore not be appropriate (Wild et al. 2010). 
Conflicting results exist concerning the effect of metformin on lipid profiles. Metformin 
impacts the lipid profile, either directly, by inhibiting hepatic acetyl-CoA carboxylase and 
activating mitochondrial fatty acid oxidation, or indirectly, through the inhibition of thecal 
androgen production (Bargiota and Diamanti-Kandarakis 2012). However, the final impact on 
lipid profile is multifactorial, and probably dependent on the BMI of the patient (Bargiota and 
Diamanti-Kandarakis 2012). Some studies have demonstrated a significant rise in HDL-C levels 
(Ibanez et al. 2000, Fleming et al. 2008, Santana et al.2004) with a drop in levels of TG (Ibanez 
et al. 2000, Rautio et al. 2005) and TC (Ibanez et al. 2000, Santana et al. 2004) during metformin 
therapy in PCOS. Others have reported no significant changes in levels of HDL-C (Luque-
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Ramirez et al. 2007), TC (Banaszewska et al. 2009, Flemming et al. 2008, Luque-Ramirez et al. 
2007, Moghetti et al. 2000, Tang et al. 2006), and TG (Banaszewska et al. 2009, Flemming et al. 
2008, Luque-Ramirez et al. 2007, Moghetti et al. 2000, Santana et al. 2004, Tang et al. 2006). 
Differences in the study subjects and the doses of metformin may account for the contrasting 
results (Bargiota and Diamanti-Kandarakis 2012). Obese PCOS women have been more resistant 
to improvements in lipid profiles (Fleming et al. 2008, Luque-Ramirez et al. 2007, Rautio et al. 
2005, Tang et al. 2006). A meta-analysis by Lord et al. 2003 detected no significant effect of 
metformin on TC, HDL-C and TG levels, whereas LDL-C levels were significantly reduced 
during treatment (Lord et al. 2003b). The RCTs included in the meta-analysis demonstrated 
many inter-study variations, thus limiting definitive conclusions. Some studies have reported no 
changes or even minor non-significant elevations in LDL-C levels during metformin therapy of 
both non-obese (Banaszewska et al. 2009, Luque-Ramirez et al. 2007, Moghetti et al. 2000) and 
obese (Luque-Ramirez et al. 2007, Rautio et al. 2005) women with PCOS.  Due to these 
conflicting results and the dangers of rising nonHDL-C levels, the expert committee of the AES 
has recommended that metformin not be used when LDL-C or non-HDL-C levels are elevated 
(Wild et al. 2010). 
The use of metformin appears to have uncontroversial positive effects on many factors of 
relevance to cardiovascular risk while the effects on other factors remain uncertain. The large 
uncertainties and discrepancies in the outcomes of the various studies reviewed stem from the 
lack of consistency between studies and call for more rigorously designed RCTs. In particular, 
future studies should span longer periods of time and follow cohorts over periods that are 
sufficient to observe outcomes. It is imperative that the studies track and factor in all possible 
factors that may affect outcome, such as lifestyle changes, diet (including details on caloric and 
carbohydrates intake), and energy expenditure.  It is also indispensible that future studies record 
baseline status such as the degree of obesity and IR, as it appears that baseline conditions have an 
impact on the effectiveness of metformin. 
Anti-obesity agents 
Orlistat, an inhibitor of pancreatic lipase and dietary fat absorption, has been evaluated 
for the treatment of PCOS. Randomized open-label trials comparing metformin and Orlistat 
therapy in PCOS women have indicated that orlistat therapy alone reduces androgen levels 
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(Jayagopal et al. 2005, Metwally et al. 2009), restores ovulation (Jayagopal et al. 2005, Metwally 
et al. 2009) , and lowers BMI (Jayagopal et al. 2005, Metwally et al. 2009) as effectively as 
metformin. Orlistat therapy alone did not improve IR (Jayagopal et al. 2005, Metwally et al. 
2009). However, a combination of Orlistat and energy restricted diet were shown to improve IR 
(Diamanti-Kandarakis et al. 2007), and, importantly, lowered advanced glycation-end products 
(Diamanti-Kandarakis et al. 2007) which are implicated in causing micro- and macro- vascular 
disease. However, clinical experience with Orlistat is limited and therefore the AES does not 
recommend its use in PCOS (Wild et al. 2010). 
OCPs 
Use of OCPs in PCOS, through is effective for reducing hirsutism, inducing the 
regression of male-pattern alopecia and restoring cyclical bleeding (Bargioata and Diamanti-
Kandarakis 2012). OCPs have, however, been shown to deteriorate the cardiovascular risk and 
metabolic profile (Bargiota and Diamanti-Kandarakis 2012), and therefore the use of OCPs in 
PCOS women may pose concern. A meta-analysis surveying the use of OCPs (with < 50 ug 
ethinyl-estradiol) in the general female population indicated that second and third generation 
OCPs increased the risk of MI/stroke (odds ratio 2.01) (Baillargeon et al. 2005). The 
deterioration of carbohydrate metabolism and of lipid profiles observed while taking OCPs may 
present a possible link between adverse cardiovascular outcome and OCP use (Nader and 
Diamanti-Kandarakis 2007). 
The effects of OCPs on carbohydrate metabolism in PCOS, as reported by different 
studies, appear to be wholly contradictory, ranging from improvements to outright diabetes 
establishment with similar contradictory results with respect to IR (Bargiota and Diamanti-
Kandarakis 2012).  
To conciliate the many variations, several authors have proposed a unifying hypothesis. 
They propose that the impact of OCs on glucose metabolism depends of several factors: the 
estrogen dose; the body type and genetic predispositions of the patient; the progestin component; 
the environment and the natural progression of PCOS of each particular patient (Mathur et al. 
2008, Nader and Diamanti-Kandarakis 2007).  
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Estrogen has been shown to impair insulin action in a dose-dependent manner (Godsland 
1996). In a randomized trial, PCOS women who received 35 µg ethinyl estradiol/ 2 mg 
cyproterone acetate perorally demonstrated impairments in insulin secretion and action, whereas 
those who were given transdermal ethinyl estradiol with peroral 2 mg cyproterone acetate 
showed no changes in these parameters (Vrbíková et al. 2004). Furthermore, a general 
population study of postmenopausal women showed that endogenous estradiol concentrations 
were closely and positively associated with rising IR (Kalish et al. 2003). In addition to the 
adverse contribution of higher estrogen levels, the metabolic perturbations that are potentially 
created by OCPs are also dependent on body type and genetic predispositions to glucose 
intolerance (Mathur et al. 2008, Nader and Diamanti-Kandarakis 2007). In randomized clinical 
trials, 35 µg ethinyl estradiol/2 mg cyproterone acetate was shown to worsen glucose tolerance in 
obese PCOS women (Morin-Papunen et al. 2000), but had no effect on glucose tolerance in lean 
PCOS women, although it caused a slight weight gain and an elevation in leptin levels in the 
latter group (Morin-Papunen et al. 2003). These results suggest that progestin-only formulations, 
such as cyproterone acetate, may be a more appropriate OCP for obese PCOS women in whom 
lifestyle modification and metformin failed to restore ovulation, or for obese PCOS adolescents 
and women desiring contraception but who are also more susceptible to metabolic perturbations 
or to thromboembolism. 
The progestin component of an OCP, especially the more androgen-like progestins, could 
also influence metabolic parameters (Mathur et al. 2008, Nader and Diamanti-Kandarakis 2007) 
and can induce IR, either directly or by delaying estrogen metabolism (Nader and Diamanti-
Kandarakis 2007). In a randomized clinical trial, after a group of young non-obese PCOS women 
had received 20 μg ethinyl estradiol/ 75 μg gestodene for over 1 year, half of the women were 
randomly selected to receive 30 µg ethinyl estradiol/3 µg drospirenone instead (Ibáñez and De 
Zegher 2004b). After 6 months, abdominal fat increased in the women who had remained on 
20 μg ethinyl estradiol/ 75 μg gestodene, whereas abdominal and total fat quantity decreased in 
those who had been switched to 30 µg ethinyl estradiol/3 µg drospirenone (Ibáñez and De 
Zegher 2004b). The authors attributed these differences to the more androgen-like properties of 
gestodene vs. the anti-androgenic ones of drospirenone (Ibáñez and De Zegher 2004b).  
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Perturbation of lipid profiles is the other frequent consequence of OCP treatment that 
poses concern in PCOS. Increased TG levels are the most common side effect of OCP use in 
women with PCOS, independently of age and BMI (Bargiota and Diamanti-Kandarakis 2012). A 
meta-analysis comparing RCTs of OCPs in PCOS indicated a rise in TG associated with OCP 
use in PCOS (Costello et al. 2007). The estrogen component is thought to cause this by lowering 
TG clearance by the liver (Bargiota and Diamanti-Kandarakis 2012). Giving PCOS women 
subdermal estrogen (Vrbíková et al. 2004) resulted in no change in TG levels. However, the 
estrogen component also has the beneficial effect of raising HDL-C by increasing the hepatic 
expression of the apoliprotein A-I gene, which in turn enhances HDL-C production. (Bargiota 
and Diamanti-Kandarakis 2012).  
Not only the estrogen component, but also progestins impact the lipid profile (Nader and 
Diamanti-Kandarakis 2007). In an RCT, 20 µg ethinyl estradiol/75 µg desogestrel was shown to 
elevate LDL-C (Gaspard et al. 2004), whereas administration of the OCP 30 µg ethinyl 
estradiol/3 µg drospirenone containing the anti-androgenic drospirenone had no effect on LDL-C 
and thus lowered the LDL-C to HDL-C ratio (Gaspard et al. 2004). Subsequent to these results, 
Gaspard et al. and other authors have advocated the use of 30 µg ethinyl estradiol/3 µg 
drospirenone in PCOS (Gaspard et al. 2004, Ibáñez and De Zegher 2004b), arguing that this 
combination alleviates many of the metabolic concerns (e.g. dyslipidemia) specific this 
syndrome (Mathur et al. 2008).   
However, 30 µg ethinyl estradiol/3 µg drospirenone may exacerbate low grade 
inflammation (Ibáñez and De Zegher 2004a) that is associated with cardiovascular risk. In a RCT 
of young non-obese PCOS women, TG and IL-6 levels increased and adiponectin levels dropped 
after 6 months of taking 30 µg ethinyl estradiol/3 µg drospirenone (Ibáñez and De Zegher 
2004a). Nine months after the beginning of the study, half of the young women were randomly 
selected to receive flutamide (62.5 mg) and metformin (850 mg) in addition to 30 µg ethinyl 
estradiol/3 µg drospirenone e (Ibáñez and De Zegher 2004a). TG and adipocytokine levels 
reverted towards normal in the group supplemented with flutamide (62.5 mg)-metformin (850 
mg) but worsened in the non-supplemented group, leading to the suggestion that future research 
should evaluate the possibility of supplementing OCPs in PCOS with flutamide-metformin 
(Ibáñez and De Zegher 2004a). However, given the hepatotoxicity of flutamide at higher doses 
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(750 mg), the authors cautioned against making the suggestion a widespread clinical practice 
before more investigations are undertaken (Ibáñez and De Zegher 2004a) and advised monitoring 
hepatic enzymes in those receiving this treatment (Ibáñez et al. 2005).  
Results from another 6 month RCT study showed that 35 µg ethinyl estradiol/2 mg 
cyproterone acetate increased IR by 25% and increased arterial stiffness, whereas 20 ug ethinyl 
estradiol/100 ug levenorgestrel plus spironolactone 50 mg twice daily demonstrated a neutral 
effect on IR and on arterial stiffness (Randeva et al. 2012).  The results from these previous 
studies have lead to advocacy that OCPs used by PCOS women should be preparations with a 
lower estrogen content in combination with anti-androgens having anti-hypertensive effects, 
such as spirinolactone (Randeva et al 2012) or drospirenone (Gaspard et al. 2004, Mathur et al. 
2008). In PCOS women with slight perturbations in the lipid profile, a progestin-only, anti-
androgenic OCP may be more appropriate. LDL-C levels > 160 mg/dL or TG levels > 250 mg/dl 
preclude the use of OCPs. 
Anti-androgens 
Androgens, as well as causing hirsutism, may contribute to the pathogenesis many of the 
metabolic abnormalities of PCOS, such as a perturbed lipid profile (Bargiota and Diamanti-
Kandarakis 2012, Sam et al. 2005). Through the activation of visceral fat cell lipolysis (Bargiota 
and Diamanti-Kandarakis 2012) and through interference with insulin signaling pathways 
(Corbould 2008), androgens may also worsen IR. 
A study of the use of the anti-androgenic flutamide in PCOS has shown that in addition to 
lowering androgen levels and improving hirsutism, this medication improved lipid profiles 
(Diamanti-Kandarakis et al. 1998). Results from another study comparing diet therapy in PCOS 
vs. flutamide and diet together showed that flutamide adds a significant effect in decreasing 
visceral fat, lowering LDL-C and improving IR than diet alone (Gambineri et al. 2004). 
Spironolactone exerts both anti-androgenic and anti-mineralocorticoid effects (Bargiota 
and Diamanti-Kandarakis 2012). It has also been effective in treating hirsutism (Bargiota and 
Diamanti-Kandarakis 2012). In a clinical trial, lean and overweight PCOS women demonstrated 
no change of IR after 12 months of taking spironolactone (Zulian et al. 2005). In the group 
taking spironolactone in association with lifestyle dietary modification, overweight and lean 
37 
 
women demonstrated a reduction of IR, as well as a reduction of TG and an elevation of HDL-C 
levels, respectively (Zulian et al. 2005). However, in another study of 3 months, women with 
PCOS women with hirsutism and a slight baseline dyslipidemia were given spironolactone 
(Nakhjavani et al. 2009). Spironolactone therapy was associated with an elevation of LDL-C and 
a reduction of HDL-C, suggesting that this drug may deteriorate the lipid profile over the short 
term and should not be administered to dyslipidemic women (Nakhjavani et al. 2009). 
Cholesterol-lowering drugs 
Several cholesterol-lowering drugs exist, but only statins have been adequately studied in 
PCOS women and are recommended by the AES expert committee for lowering cholersterol in 
PCOS women (Wild et al. 2010). The use of statins is recommended in PCOS women if LDL-C 
> 160 mg/dl, if non-HDL-C > 190 mg/dl, or if LDL-C remains > 130 mg/dl despite 3 months of 
lifestyle modification and there is the concomitant presence of 2 other CVD risk factors (Wild et 
al. 2010). If severe dyslipidemia is not corrected by lifestyle modification and statins, experts 
recommend dual pharmacotherapy with the addition of fenofibrate (Wild et al. 2010). In the 
event that TG levels are above 500 mg/dl, the expert committee also advises 4 mg daily of 
omega-3 fatty acids (Wild et al. 2010). 
Bariatric Surgery 
Follow-up studies of PCOS women having undergone bariatric surgery have indicated a 
restoration of ovulation in all PCOS women (Eid et al. 2005, Escobar-Morreale 2005), as well as 
a significant decrease in androgen levels (Escobar-Morreale 2005), a reduction of hirsutism (Eid 
et al. 2005, Escobar-Morreale 2005), mean weight loss of 41 kg (Escobar-Morreale 2005) or 
56.7% of excess weight in 1-year (Eid et al. 2005), and improvements in IR (Escobar-Morreale 
2005). Due to the risk of nutritional deficiencies and infection associated with bariatric surgery, 
the expert committee of the AES has recommended that such surgery be performed only after 
standard weight loss strategies have failed in PCOS women with a BMI greater than 40 kg/m
2
 or 
in women with a BMI greater than 35 kg/m
2
 and who also have a high-risk obesity-related 
condition (Wild et al. 2010). 
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Conclusions 
 
PCOS is an ancient evolutionary trait, most probably present before humans migrated out 
of Africa, as it is widespread and common to all races. Aggressive behavior induced by elevated 
testosterone levels, increased bone mineral density, small number of children subsequent to 
oligo-ovulation, and reduced thermogenesis as a consequence of insulin resistance, may have 
proffered survival advantages (Azziz et al. 2011). Many PCOS patients today would be sub-
fertile or fertile at the low BMI of hunter gatherers (Azziz et al. 2011). However, in the context 
of modern lifestyles, especially per western standards, PCOS women have an increased risk of 
presenting with insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, obesity, 
and dyslipidemia. These metabolic perturbations lead to chronic low grade inflammation and to 
vascular impairments that heighten the risk of cardiovascular disease. 
Insulin resistance, though obviously not the ultimate cause of PCOS, is prevalent in most 
obese and many lean PCOS cases. It plays a central role in the evolution and establishment of the 
syndrome. 
Decreased adiponectin levels reported by many of the studies reviewed in this thesis, and 
pertaining to women from different regions of the world, might represent a more ancient and 
widespread trait of PCOS that increases susceptibility to IR. Other intrinsic causative factors of 
IR are more narrowly distributed. They are present in some sub-groups of PCOS women and not 
in others, and thus may represent more recently acquired traits. These less uniformly observed 
possible causative factors, among many others that have been reported, include alterations in 
IRS-1 and IRS-2 signaling, increased activation of ERK ½ pathways, and lipolytic defects of 
visceral adipocytes. 
This review has provided a survey of many intrinsic causative factors that underlie IR, 
obesity, and the other metabolic perturbations associated with PCOS. Future investigations may 
elucidate which of these intrinsic causative factors are present in the different phenotypic sub-
groups of PCOS women. Further studies may also delineate which of these intrinsic factors are 
more common in certain geographic regions and associated ethnicities. Finally, and more 
importantly, through future investigations we may gain an understanding of which of these 
causative factors are associated with the most severe consequences. This may help foster a better 
39 
 
understanding of the pathophysiology underlying PCOS in different sub-groups and populations. 
Such knowledge could then be leveraged to devise the most optimal screening and effective 
management for women from different sub-groups and ethnicities. 
Current management of the metabolic manifestations and of the cardiovascular risk in 
PCOS is tailored to the specific presentation of each patient. Management options, depending on 
the presentation of the patient, may include lifestyle modification, insulin-sensitizing agents, 
anti-androgenic agents, anti-hypertensives, statins and bariatric surgery. 
The higher cardiometabolic risk of obese PCOS women has lead experts to advocate 
closer monitoring and more aggressive management of this group of patients. Experts have also 
advocated the annual screening of all PCOS women for IGT with the OGTT, and more frequent 
screenings for those with other DM2 risk factors, such as a family history of DM2. Some 
investigators have also suggested screening lean women with DEXA for excess abdominal fat 
accumulations, as lean PCOS women with a higher proportion of abdominal fat relative to BMI-
comparable control women are more susceptible to developing insulin resistance and may 
therefore benefit from more aggressive prevention. 
Central abdominal fat accumulation has been associated with insulin resistance, chronic 
inflammation, and harmful ectopic fat accumulations. Studies evaluating abdominal fat 
accumulation in PCOS women relative to BMI-comparable controls have reported contradictory 
results. This highlights the need for more studies that would quantify ectopic, visceral and 
subcutaneous abdominal fat by CT or MRI, in order to provide definitive answers about the 
relationship between PCOS and visceral fat. 
Authors of studies evaluating the effects of OCPs and of metformin on certain aspects of 
the cardiometabolic profile, such as on the lipid profile, have reported contradictory results. This 
demonstrates the need for future RCTs evaluating women with PCOS to span longer periods of 
time, and to track all possible factors that may affect outcome, such as baseline status, lifestyle 
changes and diet (including details on caloric and carbohydrates intake). In particular, women 
with long-standing metabolic disturbances and those with the most severe metabolic profiles 
were reported to be more resistant to current management strategies and medications. This fact 
points to the need for future studies that focus on devising more effective ways to manage this 
resistant group of PCOS women. 
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